147 related articles for article (PubMed ID: 17146741)
1. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
Foster J; Black J; LeVea C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF
Ann Surg Oncol; 2007 Feb; 14(2):752-8. PubMed ID: 17146741
[TBL] [Abstract][Full Text] [Related]
2. Correlation between expression of cyclooxygenase-2 and the presence of CD4+ infiltrating T-lymphocyte in human primary hepatocellular carcinoma.
Gao YW; Chen YX; Wang ZM; Zhou LD; Li XY; Li LX; Luo QZ; Tian W; Fu CY; Zhou JH
Hepatogastroenterology; 2008; 55(82-83):345-50. PubMed ID: 18613363
[TBL] [Abstract][Full Text] [Related]
3. Akt expression may predict favorable prognosis in cholangiocarcinoma.
Javle MM; Yu J; Khoury T; Chadha KS; Iyer RV; Foster J; Kuvshinoff BW; Gibbs JF; Geradts J; Black JD; Brattain MG
J Gastroenterol Hepatol; 2006 Nov; 21(11):1744-51. PubMed ID: 16984600
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor expression and gene copy number in fibrolamellar hepatocellular carcinoma.
Buckley AF; Burgart LJ; Kakar S
Hum Pathol; 2006 Apr; 37(4):410-4. PubMed ID: 16564914
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 expression is dependent upon epidermal growth factor receptor expression or activation in androgen independent prostate cancer.
Jia RP; Xu LW; Su Q; Zhao JH; Li WC; Wang F; Xu Z
Asian J Androl; 2008 Sep; 10(5):758-64. PubMed ID: 18645679
[TBL] [Abstract][Full Text] [Related]
6. Novel and existing mutations in the tyrosine kinase domain of the epidermal growth factor receptor are predictors of optimal resectability in malignant peritoneal mesothelioma.
Foster JM; Gatalica Z; Lilleberg S; Haynatzki G; Loggie BW
Ann Surg Oncol; 2009 Jan; 16(1):152-8. PubMed ID: 18998063
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis.
Sasaki A; Ishikawa K; Haraguchi N; Inoue H; Ishio T; Shibata K; Ohta M; Kitano S; Mori M
Ann Surg Oncol; 2007 Mar; 14(3):1191-9. PubMed ID: 17195907
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor in human hepatocellular carcinoma.
Hamazaki K; Yunoki Y; Tagashira H; Mimura T; Mori M; Orita K
Cancer Detect Prev; 1997; 21(4):355-60. PubMed ID: 9232327
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
10. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
Cortas T; Eisenberg R; Fu P; Kern J; Patrick L; Dowlati A
Lung Cancer; 2007 Mar; 55(3):349-55. PubMed ID: 17161498
[TBL] [Abstract][Full Text] [Related]
11. Proline-directed protein kinase FA is a powerful and independent prognostic predictor for progression and patient survival of hepatocellular carcinoma.
Hsu YC; Fu HH; Jeng YM; Lee PH; Yang SD
J Clin Oncol; 2006 Aug; 24(23):3780-8. PubMed ID: 16754939
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of EGF receptor expression in early glottic cancer.
Demiral AN; Sarioglu S; Birlik B; Sen M; Kinay M
Auris Nasus Larynx; 2004 Dec; 31(4):417-24. PubMed ID: 15571917
[TBL] [Abstract][Full Text] [Related]
13. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection.
Schmitz KJ; Wohlschlaeger J; Lang H; Sotiropoulos GC; Malago M; Steveling K; Reis H; Cicinnati VR; Schmid KW; Baba HA
J Hepatol; 2008 Jan; 48(1):83-90. PubMed ID: 17998146
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.
Khorana AA; Ryan CK; Cox C; Eberly S; Sahasrabudhe DM
Cancer; 2003 Feb; 97(4):960-8. PubMed ID: 12569594
[TBL] [Abstract][Full Text] [Related]
15. P53 and EGFR expression in colorectal cancer: a reappraisal of 'old' tissue markers in patients with long follow-up.
Theodoropoulos GE; Karafoka E; Papailiou JG; Stamopoulos P; Zambirinis CP; Bramis K; Panoussopoulos SG; Leandros E; Bramis J
Anticancer Res; 2009 Feb; 29(2):785-91. PubMed ID: 19331236
[TBL] [Abstract][Full Text] [Related]
16. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
17. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome.
Kramer C; Klasmeyer K; Bojar H; Schulz WA; Ackermann R; Grimm MO
Cancer; 2007 May; 109(10):2016-24. PubMed ID: 17394193
[TBL] [Abstract][Full Text] [Related]
18. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma.
Lager DJ; Slagel DD; Palechek PL
Mod Pathol; 1994 Jun; 7(5):544-8. PubMed ID: 7937720
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor expression and activation in neuroendocrine tumours.
Shah T; Hochhauser D; Frow R; Quaglia A; Dhillon AP; Caplin ME
J Neuroendocrinol; 2006 May; 18(5):355-60. PubMed ID: 16629834
[TBL] [Abstract][Full Text] [Related]
20. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer.
Noordhuis MG; Eijsink JJ; Ten Hoor KA; Roossink F; Hollema H; Arts HJ; Pras E; Maduro JH; Reyners AK; de Bock GH; Wisman GB; Schuuring E; van der Zee AG
Clin Cancer Res; 2009 Dec; 15(23):7389-97. PubMed ID: 19920104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
